Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Short term Debt (2020 - 2025)

Gain Therapeutics has reported Short term Debt over the past 6 years, most recently at $125545.0 for Q3 2025.

  • Quarterly results put Short term Debt at $125545.0 for Q3 2025, up 6.14% from a year ago — trailing twelve months through Sep 2025 was $125545.0 (up 6.14% YoY), and the annual figure for FY2024 was $110177.0, down 7.26%.
  • Short term Debt for Q3 2025 was $125545.0 at Gain Therapeutics, roughly flat from $126108.0 in the prior quarter.
  • Over the last five years, Short term Debt for GANX hit a ceiling of $126108.0 in Q2 2025 and a floor of $44287.0 in Q1 2021.
  • Median Short term Debt over the past 5 years was $109281.0 (2023), compared with a mean of $102318.0.
  • Biggest five-year swings in Short term Debt: surged 358.88% in 2021 and later fell 7.26% in 2024.
  • Gain Therapeutics' Short term Debt stood at $103826.0 in 2021, then increased by 4.15% to $108135.0 in 2022, then rose by 9.86% to $118797.0 in 2023, then fell by 7.26% to $110177.0 in 2024, then increased by 13.95% to $125545.0 in 2025.
  • The last three reported values for Short term Debt were $125545.0 (Q3 2025), $126108.0 (Q2 2025), and $113121.0 (Q1 2025) per Business Quant data.